The selection result of the third batch of national centralized purchasing is officially announced. 

On August 20, Shanghai United Procurement Office released the selection result of the third batch of national centralized purchasing.

 

 

According to information, compared with the highest effective declared prices, the average price reduction of the 55 common varieties was greater than 70%, with the highest drop of 98.72% -- according to the data from Menet.com.cn, a total of 16 varieties showed a sharp price reduction, with a drop of more than 90%.

It could be seen from the final results of proposed selection, the pharmaceutical enterprises in the first echelon of China constituted the main force of this centralized purchasing, while the innovative drugenterprises have exited in succession. (Click here to view details)

 

02

In-depth interpretation of the third batch of national centralized purchasing

How about the specific situation of this centralized purchasing? Why is it that some people are calm, while others are not? What is the influence on the hospital medication later? Dingxiangyuan will bring an in-depth interpretation.

 

 

After a year and a half, purchasing with specified quantity has experienced from a series of panic falls in the stock market initially to calmness now, and the market and companies also look more relaxed.

Compared with the previous two batches, the foreign company's innovative drug market share is increased, but appears calmer; many enterprises of China can obtain incremental market, but the competition is still fierce, witnessing sharp decline in succession. (Click here to view details)

 

03

A new breakthrough in the field of 10-billion anti-fibrosis 

According to the recent data of INSIGHT Database, Beijing Tide Pharmaceutical Co., Ltd., a subsidiary of Sino Biopharmaceutical, has submitted an IND application for its independently developed drug, TDI01 (first class new drug), and been accepted by CDE.

The public data show that TDI01, a kind of oral small molecule drug with new target and new mechanism, serves as the inhibitor for highly selective RHO/RHO associated coiled-coil forming protein kinase 2 (ROCK2), and it has been listed in the major new drug development category of the National 13th Five-year Plan, with the indications including pulmonary fibrosis, and nonalcoholic fatty hepatitis, namely, the FIRST-IN-CLASS drug in such indication field. (Click here to view details)

 

04

Kelun Industry Group [Paclitaxel for Injection (Albumin Bound)] is approved. 

On August 18, the official website of the National Medical Products Administration disclosed that Kelun Industry Group's Paclitaxel for Injection (Albumin Bound) was approved, and the approval of category 4 according to the new registration classification was regarded as having passed the consistent evaluation.

 

 

Paclitaxel for Injection (Albumin Bound), developed by ABRAXIS BIOSCIENCE, USA, is an anti-microtubule drug used to treat metastatic breast cancer with no respond to combined chemotherapy or breast cancer that relapses within six months of adjuvant chemotherapy. (Click here to view details)

 

05

Hengrui Tim-3 monoclonal antibody is clinically initiated. 

INSIGHT Database revealed that Hengrui had launched a phase I clinical study of SHR-1702 for the treatment of myelodysplasia syndrome, or acute myeloid leukemia on August 17.

 

 

There has been no TIM-3 antibody drug approved to market yet. INSIGHT global drug database reveals that, there are a total of 10 new drugs for TIM-3 targets in development at present and almost all of them are in the early clinical study, of which NVS MBG 453 is of the fastest development progress, stepping into the phase iii clinical study for the clinical indications of chronic monocytic leukemia and myelodysplastic syndrome. (Click here to view details)

 

06

China's retail pharmacy market reaches RMB 660 billion for the first time 

In August 2020, the National Medical Products Administration released the Annual Statistical Report on Drug Administration in 2019. By the end of 2019, there were 544,000 enterprises with Drug Trade Licenses nationwide, of which 14,000 were wholesale enterprises, there were 6,701 retail chain enterprises, and 290,000 retail chain stores, and there were 234,000 retail pharmacies.

 

 

According to the data from Menet.com.cn, the sales volume of offline and online pharmacies (including drugs and non-drugs) in China reached RMB 662 billion in 2019 based on the average terminal retail prices, with a year-on-year growth of 8.4%. Physical pharmacies accounted for more than 80% of the total, while online pharmacies reached RMB 100 billion for the first time. (Click here to view details)

 

07

Sino Pharmaceuticals participated in the 2-billion compound preparation 

On August 21, the official website of CDE revealed that, the Irbesartan and Hydrochlorothiazide tablets (category 4 generic drug) of Sino Pharmaceuticals had been approved to market.

 

 

Irbesartan and Hydrochlorothiazide tablets belong to a super variety of cardiovascular system drugs (more than RMB 2 billion project), and it is also a variety in the first round of centralized procurement (4+7, alliance expansion) catalog. With the entry of domestic generic drugs, the market share of the innovative drug Sanofi has been "declining". (Click here to view details)

 

08

Successful control of type 1 diabetes in mice by human islets organs

Accounting for about 90% of the total number of various childhood diabetes, type 1 diabetes is a major pediatric endocrine diseases endangering children's health.

 

 

The incidence rate in China is 2/100,000 ~ 5/100,000 in recent years, and the average annual growth of its incidence in children under 5 years old is 5%~34%.

Investigators in the Salk Institute for Biological Studies found that, the human islets-like organs generated from stem cells could evade immune attack, and control type 1 diabetes in mice. (Click here to view details)

 

09

DNA methylation can accelerate aging and lower resistance 

Investigators have found that epigenetic changes may be critical for the development of complex diseases, accelerated aging or sharp cognitive decline with the advances in biotechnology and the creation of a global epigenetic map in recent years.

 

 

Epigenetics refers to a process by which chemicals attached to DNA control its activity. Epigenetic changes, which can be passed on to future generations, may be crucial for accelerated ageing and the accompanying decline in cognitive and physical functions.

Epigenetic modifications causing changes in gene expression can be caused by a number of biological processes, including one of the biological processes of concern to investigators: DNA methylation. (Click here to view details)

 

10

Two well-known pharmaceutical companies announced an alliance. 

Huabei Pharmaceutical announced the signing of the Strategic Cooperation Framework Agreement with SINOPHARM-Chongqing Pharmaceutical Business Consortium recently.

This was another strategic cooperation between North China Pharmaceuticals and pharmaceutical commercial enterprises since it cooperated with Sinopharm Holding on July 17 and Shanghai Pharmaceutical Holding on July 29. (Click here to view details)